 The evaluation of the heme chip, a low-cost point-of-care diagnostic device for sickle cell disease, revealed several factors that contributed to its successful translation from laboratory to market. These included NE and CTSA hub support, pilot program funding, university resources, entrepreneurship training, due diligence, and collaboration with industry partners. Additionally, overcoming challenges such as proving novelty, manufacturing costs, fundraising, and academic-industry relations proved essential to the success of the heme chip's translation. This case study provides valuable insight into the complexities of translating medical devices and suggests potential strategies for future funding mechanisms and infrastructures to ensure successful translation. This article was authored by Kelly Qua, Shannon M. Swietkowski, Imit A. Gurkin, and others.